Professor Peter Gibbs was awarded the 2019 Innovation Fund grant. He received $200,000 to conduct the pilot study, ‘An organoid sensitivity testing driven umbrella study for patients with refractory metastatic colorectal cancer.’
Professor Gibbs’ study will enrol 30 patients with metastatic colorectal cancer who have exhausted all other treatment options. Fresh biopsies of their cancers will be obtained and cultured in the laboratory to establish patient derived tumour organoids (PDTOs). A variety of well-established and new therapies will be tested on the organoids, in order to find any effective treatments that can be offered. The best treatment for each patient will then be individually allocated according to the results of these analyses.
“I am thrilled that we have received the Innovation Fund grant to conduct such an important study,” says Professor Gibbs. “This grant will enable us to test a new development in personalised bowel cancer treatment that could give hope to people who have no other options.”
The Innovation Fund grant is made possible through generous contributions from the Spencer Gibson Foundation, the His Honour Alan Bishop Fund and with donations raised through the GI Cancer Institute’s Gutsy Challenge.